Ark floats gene therapy's boat, for now

sea-maid submitted, created time 2 months 1 week (www.nature.com)

In August, gene therapy's turbulent ride through the clinical rapids took a new twist as Ark Therapeutics released positive top-line results from a phase 3 trial of its adenoviral gene therapy Cerepro (sitimagene ceradenovec) for malignant brain tumors. Although the news boosted the London-based firm's shares, the course to market authorization and registration remains strewn with uncertainty—as Introgen, of Austin, Texas, found, to its cost, when the U.S

Submit comment | Blog It | Email It | Keywords: Li-Fraumeni sitimagene ceradenovec li-fraumeni syndrome head and neck cancer cancer Cerepro clinical trials funding big pharma pharma economics Ark Therapeutics gene therapy